Teva Pharmaceuticals Ltd. Copaxone® (glatiramer acetate) 20 & 40 mg/ml solution for injection in pre-filled syringe: summary of product characteristics. 2022. Available from https://www.medicines.org.uk/emc/product/183/smpc and https://www.medicines.org.uk/emc/product/7046/smpc. Accessed 3 Aug 2024.

Teva Neuroscience Inc. COPAXONE® (glatiramer acetate injection): US Prescribing Information. ***November 2023. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020622s116lbl.pdf. Accessed 1 Aug 2024.

Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol. 2012;22(12):124.

Article  Google Scholar 

Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5(5):247–53.

Article  PubMed  PubMed Central  Google Scholar 

Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler. 2016;22(6):810–6.

Article  CAS  PubMed  Google Scholar 

MacDonald SC, McElrath TF, Hernández-Díaz S. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis. Pharmacoepidemiol Drug Saf. 2019;28(4):556–60.

Article  PubMed  Google Scholar 

Nguyen AL, Havrdova EK, Horakova D, Izquierdo G, Kalincik T, van der Walt A, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. Mult Scler Relat Disord. 2019;28:235–43.

Article  PubMed  Google Scholar 

Sandberg-Wollheim M, Neudorfer O, Grinspan A, Weinstock-Guttman B, Haas J, Izquierdo G, et al. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. Int J MS Care. 2018;20(1):9–14.

Article  PubMed  PubMed Central  Google Scholar 

Ciplea AI, Kurzeja A, Thiel S, Haben S, Alexander J, Adamus E, et al. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis—COBRA study. Mult Scler. 2022;28(10):1641–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaplan S, Zeygarnik M, Stern T. Pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate during pregnancy and breastfeeding. Drug Saf. 2022;45(4):345–57.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP): product- or population-specific considerations III: pregnant and breastfeeding women. 2019. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-product-population-specific-considerations-iii_en.pdf. Accessed 3 Aug 2021.

University of California San Francisco (UCSF) Health. Pregnancy: the three trimesters. 2020. Available from https://www.ucsfhealth.org/conditions/pregnancy. Accessed 25 Feb 2025.

Holmes LB, Westgate MN. Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens. Birth Defects Res A Clin Mol Teratol. 2011;91(9):807–12.

Article  CAS  PubMed  Google Scholar 

Centers for Disease Control and Prevention (CDC). Metropolitan Atlanta Congenital Defects Program (MACDP). https://www.cdc.gov/birth-defects/tracking/?CDC_AAref_Val=https://www.cdc.gov/ncbddd/birthdefects/macdp.html. Accessed 25 Feb 2025.

European network for surveillance of congenital anomalies (EUROCAT). European surveillance of congenital anomalies (EUROCAT) Guide 1.4 and reference documents. 2018. Available from https://eu-rd-platform.jrc.ec.europa.eu/sites/default/files/Full_Guide_1_4_version_28_DEC2018.pdf. Accessed 29 Aug 2021.

Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects–Atlanta, Georgia, 1978–2005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1–5.

Google Scholar 

EUROCAT. European network for surveillance of congenital anomalies (EUROCAT)—prevalence charts and tables. Available from https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence_en. Accessed 24 May 2023.

Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62(5):1494–503.

Article  PubMed  PubMed Central  Google Scholar 

Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101–10.

Article  CAS  Google Scholar 

Robert Koch Institute. Reference percentiles for anthropometric measures and blood pressure based on the German Health Interview and Examination Survey for Children and Adolescents 2003–2006 (KiGGS). 2016. https://edoc.rki.de/bitstream/handle/176904/3271/23s3ntHQtKbus.pdf?sequence=1&isAllowed=y. Accessed 25 Feb 2025.

MSD and the MSD Manuals. WHO infant weight for length percentiles (<24 months). 2022 [cited 2022 January 28]. Available from https://www.msdmanuals.com/professional/multimedia/clinical-calculator/who-infant-weight-for-length-percentiles-24-months. Accessed 24 May 2023.

Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: final data for 2022. Natl Vital Stat Rep. 2024;73(2):1–56.

PubMed  Google Scholar 

Rossen LM, Ahrens KA, Branum AM. Trends in risk of pregnancy loss among US women, 1990–2011. Paediatr Perinat Epidemiol. 2018;32(1):19–29.

Article  PubMed  Google Scholar 

Ventura SJ, Mosher WD, Curtin SC, Abma JC, Henshaw S. Highlights of trends in pregnancies and pregnancy rates by outcome: estimates for the United States, 1976–96. Natl Vital Stat Rep. 1999;47(29):1–9.

PubMed  Google Scholar 

Martin JA, Hamilton BE, Osterman MJK, Driscoll AK. Births: final data for 2019. Natl Vital Stat Rep. 2021;70(2):1–51.

PubMed  Google Scholar 

Moccia M, Affinito G, Fumo MG, Giordana R, Di Gennaro M, Mercogliano M, et al. Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020. J Neurol Neurosurg Psychiatry. 2023;94(9):689–97.

Article  PubMed  Google Scholar 

Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 2010;257(12):2020–3.

Article  CAS  PubMed  Google Scholar 

Hallare J, Gerriets V. Half Life. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing LLC.; 2022.

Lorefice L, Fronza M, Fenu G, Frau J, Coghe G, D’Alterio MN, et al. Effects of pregnancy and breastfeeding on clinical outcomes and MRI measurements of women with multiple sclerosis: an exploratory real-world cohort study. Neurol Ther. 2022;11(1):39–49.

Article  PubMed  Google Scholar 

Hellwig K, Gold R. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol. 2011;258(3):502–3.

Article  PubMed  Google Scholar 

Vukusic S, Michel L, Leguy S, Lebrun-Frenay C. Pregnancy with multiple sclerosis. Rev Neurol (Paris). 2021;177(3):180–94.

Article  CAS  PubMed  Google Scholar 

Portaccio E, Tudisco L, Pastò L, Razzolini L, Fonderico M, Bellinvia A, et al. Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Mult Scler. 2022;28(3):472–9.

Article  CAS  PubMed  Google Scholar 

Kaplan S, Zeygarnik M, Stern T, Hellwig K. Pregnancy and fetal outcomes following maternal exposure to glatiramer acetate in all three trimesters of pregnancy. Eur J Neurol. 2023;30(12):3890–5.

Article  PubMed  Google Scholar 

Kohlhuber M, Rebhan B, Schwegler U, Koletzko B, Fromme H. Breastfeeding rates and duration in Germany: a Bavarian cohort study. Br J Nutr. 2008;99(5):1127–32.

Article  CAS  PubMed  Google Scholar 

MICH. Increase the proportion of infants who are breastfed exclusively through age 6 months—MICH-15 healthy people 2030. 2020. Available from https://health.gov/healthypeople/objectives-and-data/browse-objectives/infants/increase-proportion-infants-who-are-breastfed-exclusively-through-age-6-months-mich-15. Accessed 1 Aug 2024.

Bove RM, Houtchens MK. Pregnancy management in multiple sclerosis and other demyelinating diseases. Continuum (Minneap Minn). 2022;28(1):12–33.

PubMed  Google Scholar 

Ciplea AI, Kurzeja A, Thiel S, Haben S, Adamus E, Hellwig K. Safety evaluations of offspring breastfed by mothers receiving glatiramer acetate for relapsing multiple sclerosis. Mult Scler Relat Disord. 2023;75: 104771.

Article  CAS  PubMed  Google Scholar 

Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–88.

Article  PubMed  Google Scholar 

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25(2):215–37.

Article  CAS  PubMed  Google Scholar 

ECTRIMS. Oral presentations. Mult Scler. 2021;2021(27):3–133.

Google Scholar 

Medscape. Updated MS Guidelines Advocate Earlier, More Aggressive Treatment. 2021 [cited 2024 September 5]. Available from https://www.medscape.com/viewarticle/961161#vp_1. Accessed 5 Sept 2024.

Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, et al. Treatment optimization in multiple sclerosis: Canadian MS working group recommendations. Can J Neurol Sci. 2020;47(4):437–55.

Article  PubMed